ArticleNPJ breast cancer2022

Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT).

Tal Sella et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.